LYFT Inc vs Medtronic PLC — how do they compare? LYFT Inc trades at $15.29 (market cap $5.86B), while Medtronic PLC trades at $82.35 (market cap $106.61B). The key difference: Medtronic PLC is far larger — about 18.2× LYFT Inc's market cap, and Medtronic PLC pays a 3.46% dividend while LYFT Inc pays none. Which is the better fit depends on your goals.
| LYFT | MDT | |
|---|---|---|
Market Cap | $5.86B | $106.61B |
Sector | Industrials | Health |
52-Week High | $24.57 | $105.35 |
52-Week Low | $12.65 | $73.75 |
Enterprise Value | $5.39B | $125.36B |
Dividend Yield | — | 3.46% |
Signals from Pluang's Aura AI — not financial advice
Lyft trades at $15.39, down 0.84% on the day, with mixed technical signals showing a bullish moving average trend but neutral oscillators. The company demonstrates strong revenue growth, reaching $6.32B in 2025 with a remarkable net income margin of 43.82%, though recent quarterly EPS results have been inconsistent with two misses and one beat. Analyst consensus leans neutral with 57.6% hold ratings but offers a $17.86 price target suggesting 16% upside potential.
Lyft presents a compelling valuation case with a low P/E of 2.27 and P/S of 0.98, supported by improving cash flow trends and strategic expansions into new markets. However, risks include competitive pressure from Uber, inconsistent earnings performance, and regulatory scrutiny over pricing practices. The upcoming Q2 2026 earnings report on August 6 will be critical for validating the company's growth trajectory.
Medtronic (MDT) trades at $83.54, up 0.41% today, with a bullish technical signal from moving averages. The company reported strong revenue growth to $33.54B in 2025 and has beaten EPS estimates for three consecutive quarters. Recent acquisitions, including SPR and Scientia Vascular, expand its pain therapy and neurovascular portfolios. Valuation ratios show a P/E of 22.31 and P/S of 2.95, with a consensus price target of $97.50 implying significant upside.
The outlook is positive, supported by robust fundamentals, analyst optimism, and strategic expansions. Key risks include rising debt levels and competitive pressures in medical technology. With no sell ratings from analysts and a dividend yield near a decade high, MDT presents a compelling long-term opportunity for growth and income investors, though macroeconomic and execution risks warrant monitoring.
Trailing returns across standard periods
Latest headlines on both assets
Lyft is the second-largest ride-sharing service provider in the U.S., connecting riders and drivers over the Lyft app. Lyft recently entered the Canadian market in an effort to expand its market outside the U.S. Incorporated in 2013, Lyft offers a variety of rides via private vehicles, including traditional private rides, shared rides, and luxury ones. Besides ride-share, Lyft also has entered the bike- and scooter-share market to bring multimodal transportation options to users.
Read more on LYFT →One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for almost 50% of the company's total sales.
Read more on MDT →